Cytarabin Hikma: Uses, Dosage & Side Effects

What Is Cytarabin Hikma and What Is It Used For?

Cytarabin Hikma contains cytarabine, a synthetic nucleoside analogue of deoxycytidine that has been a fundamental component of leukemia treatment since its introduction in the 1960s. Also known by its abbreviation ara-C (arabinofuranosyl cytidine) or cytosine arabinoside, this medication belongs to the antimetabolite class of anticancer drugs. Antimetabolites are substances that closely resemble natural compounds needed for normal cell processes but are different enough to interfere with cellular functions, particularly DNA synthesis. Cytarabine specifically mimics the naturally occurring nucleoside deoxycytidine, which is one of the four building blocks of DNA.

Once inside the cell, cytarabine undergoes a series of phosphorylation steps, first being converted to cytarabine monophosphate (ara-CMP) by deoxycytidine kinase, and then to its active triphosphate form, cytarabine triphosphate (ara-CTP). The active metabolite ara-CTP competes with the natural substrate deoxycytidine triphosphate (dCTP) for incorporation into DNA by DNA polymerase alpha. When ara-CTP is incorporated into the growing DNA strand, it causes chain termination and inhibition of further DNA synthesis. Additionally, cytarabine inhibits DNA polymerase beta, which is involved in DNA repair mechanisms. These combined actions make cytarabine particularly effective against rapidly dividing cells that are actively synthesizing DNA – making it an S-phase specific agent.

The selectivity of cytarabine for the S-phase of the cell cycle has important implications for how it is administered clinically. Because only a fraction of cancer cells are in the S-phase at any given time, prolonged exposure or repeated dosing is needed to maximize the proportion of cancer cells affected. This is why cytarabine is often given as a continuous intravenous infusion over several days rather than as a single bolus injection, particularly during induction chemotherapy for acute leukemia.

Cytarabin Hikma is approved and used internationally for the following conditions:

• Acute myeloid leukemia (AML): Cytarabine is the single most important drug in AML treatment. It forms the backbone of standard induction therapy, typically given as a continuous intravenous infusion at 100–200 mg/m²/day for 7 days combined with an anthracycline such as daunorubicin for 3 days (the “7+3” regimen). High-dose cytarabine (HiDAC) is widely used in consolidation therapy, particularly for patients with favorable-risk cytogenetics.
• Acute lymphoblastic leukemia (ALL): Cytarabine is included in many multi-agent chemotherapy protocols for ALL in both children and adults, often as part of consolidation or intensification phases. It is particularly important in protocols for the treatment of mature B-cell ALL (Burkitt-type).
• Chronic myeloid leukemia (CML): Although tyrosine kinase inhibitors have largely replaced cytotoxic chemotherapy for CML, cytarabine may still be used in blast crisis or in specific combination regimens.
• Non-Hodgkin lymphoma: Cytarabine is a component of several salvage chemotherapy regimens for relapsed or refractory non-Hodgkin lymphoma, including DHAP (dexamethasone, high-dose ara-C, cisplatin) and R-DHAP protocols.
• Meningeal leukemia and lymphoma: Administered intrathecally (directly into the cerebrospinal fluid via lumbar puncture), cytarabine is used for the prophylaxis and treatment of central nervous system (CNS) involvement by leukemia and lymphoma. Intrathecal cytarabine is essential because systemic (intravenous) doses do not achieve adequate drug levels in the cerebrospinal fluid.

Cytarabine holds a place on the WHO Model List of Essential Medicines, reflecting its critical importance in global cancer treatment. The European LeukemiaNet (ELN) 2022 recommendations and the NCCN Clinical Practice Guidelines both emphasize cytarabine as an indispensable component of AML treatment. Despite the development of many newer agents, cytarabine remains irreplaceable in the management of acute leukemias and continues to form the backbone of curative chemotherapy regimens worldwide.

What Should You Know Before Receiving Cytarabin Hikma?

Before starting treatment with Cytarabin Hikma, your medical team will conduct a thorough assessment of your overall health, blood counts, liver and kidney function, and any existing medical conditions. Because cytarabine is a potent cytotoxic agent with significant toxicities, careful patient evaluation is essential to minimize risks and ensure the best possible outcomes. The following sections describe the key considerations your healthcare team will evaluate.

Contraindications

There are specific situations in which Cytarabin Hikma must not be used. Understanding these absolute contraindications is essential before treatment begins.

• Hypersensitivity: Do not receive Cytarabin Hikma if you have a known allergy to cytarabine or any of the excipients in the formulation. Allergic reactions to cytarabine are rare but can range from skin rash to more severe hypersensitivity reactions.
• Active severe infection: Treatment should generally not be initiated in patients with uncontrolled, life-threatening infections, as cytarabine-induced immunosuppression can worsen the infection. However, in the context of acute leukemia, the balance between the urgency of cancer treatment and infection risk is a clinical judgment made by the treating physician.

Warnings and Precautions

Before and during treatment with Cytarabin Hikma, your doctor will carefully monitor for the following potential complications:

• Myelosuppression: This is the primary and expected toxicity of cytarabine. The severity depends on the dose, schedule, and route of administration. The nadir (lowest point) of blood counts typically occurs 7–14 days after standard-dose therapy, with recovery over 2–3 weeks. During the period of severe neutropenia, patients are extremely vulnerable to bacterial, viral, and fungal infections.
• Cerebellar and CNS toxicity: High-dose cytarabine (doses above 1 g/m²) can cause cerebellar dysfunction, presenting as difficulty with coordination (ataxia), unsteady gait, slurred speech (dysarthria), and involuntary eye movements (nystagmus). This toxicity may be irreversible. Risk factors include age over 50 years, impaired renal function, impaired hepatic function, and previous CNS treatment including radiation therapy. Neurological assessment must be performed before each high-dose cycle, and treatment must be discontinued immediately at the first sign of cerebellar dysfunction.
• Cytarabine syndrome: A characteristic syndrome may develop 6–12 hours after drug administration, featuring fever, muscle pain (myalgia), bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and general malaise. This syndrome can be treated or prevented with corticosteroids. It is important to distinguish this syndrome from infection, which requires different management.
• Hepatotoxicity: Cytarabine can cause liver damage, manifested as elevated liver enzymes, jaundice, and in severe cases hepatic dysfunction. The risk is increased with high-dose regimens and in patients with pre-existing liver disease. Liver function tests should be monitored regularly throughout treatment.
• Pulmonary toxicity: Non-cardiogenic pulmonary edema, acute respiratory distress syndrome (ARDS), and other pulmonary complications have been reported, particularly with high-dose cytarabine. Patients who develop respiratory symptoms during treatment require prompt evaluation.
• Gastrointestinal toxicity: Nausea, vomiting, diarrhea, and oral mucositis (painful mouth ulcers) are common. In severe cases, bowel necrosis, perforation, or pseudomembranous colitis may occur. Adequate antiemetic prophylaxis and monitoring for gastrointestinal complications are essential.
• Ocular toxicity: High-dose cytarabine can cause conjunctivitis and corneal toxicity (keratitis). Prophylactic corticosteroid eye drops are typically administered with high-dose regimens to prevent or minimize these effects. Patients should report any eye symptoms promptly.
• Tumor lysis syndrome: Rapid destruction of leukemia cells can release large amounts of intracellular contents into the bloodstream, leading to hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. This metabolic emergency can cause acute kidney injury and cardiac arrhythmias. Preventive measures include adequate hydration and allopurinol or rasburicase.
• Skin reactions: Rashes, including maculopapular eruptions, palmar-plantar erythrodysesthesia (hand-foot syndrome), and in rare cases more severe reactions, may occur. Alopecia (hair loss) is also common.
• Immunosuppression: Cytarabine suppresses the immune system, increasing susceptibility to infections including opportunistic infections. Live vaccines should not be administered to patients receiving cytarabine or for an appropriate period after treatment completion.

Pregnancy and Breastfeeding

Cytarabine is known to be teratogenic (capable of causing birth defects) and embryotoxic based on both animal studies and case reports in humans. It can cause serious harm to a developing fetus, particularly during the first trimester. Cytarabine should not be used during pregnancy unless the potential benefit to the mother justifies the risk to the fetus. In the context of acute leukemia, where delaying treatment may be life-threatening, the decision to treat during pregnancy must be made on an individual basis with full discussion of the risks.

Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose of cytarabine. Men should also use effective contraception during treatment and for at least 3 months after the last dose. A pregnancy test should be performed before starting treatment.

Breastfeeding must be discontinued during cytarabine treatment. It is not known whether cytarabine or its metabolites are excreted in human breast milk, but given its mechanism of action and potential toxicity, a risk to the breastfed infant cannot be excluded. Breastfeeding should not be resumed until an appropriate washout period after the last dose, as determined by the treating physician.

Cytarabine may impair fertility in both men and women. Men should consider sperm cryopreservation (banking) before starting treatment. Women should discuss fertility preservation options, such as oocyte or embryo cryopreservation, with their healthcare team before initiating therapy, if time and clinical circumstances permit.

Renal and Hepatic Impairment

Patients with impaired kidney or liver function may be at increased risk of toxicity from cytarabine. Renal impairment can reduce the clearance of cytarabine and its metabolites, potentially increasing drug exposure and toxicity. Hepatic impairment may also affect drug metabolism. Dose adjustments or increased monitoring may be necessary in patients with significant renal or hepatic dysfunction. High-dose cytarabine should be used with extreme caution in patients with renal impairment, as the risk of neurotoxicity is substantially increased.

How Does Cytarabin Hikma Interact with Other Drugs?

Drug interactions with cytarabine can occur through several mechanisms, including pharmacokinetic interactions (affecting drug absorption, metabolism, or elimination) and pharmacodynamic interactions (affecting the drug’s action at its target). Because cytarabine is almost always used as part of multi-agent chemotherapy regimens, understanding these interactions is critical for optimizing treatment efficacy and minimizing toxicity. It is essential to inform your medical team about all medications, supplements, and herbal products you are taking or have recently taken.

Major Interactions

Minor Interactions

Because cytarabine is primarily inactivated by cytidine deaminase rather than the cytochrome P450 enzyme system, it has fewer metabolic drug interactions than many other chemotherapy agents. However, any substance that affects the activity of deoxycytidine kinase (the enzyme that activates cytarabine) or cytidine deaminase (the enzyme that inactivates it) could theoretically alter the drug’s efficacy or toxicity. The clinical significance of such interactions continues to be studied.

What Is the Correct Dosage of Cytarabin Hikma?

The dosage of Cytarabin Hikma is highly individualized and depends on numerous factors including the type and stage of cancer being treated, the specific chemotherapy protocol, the patient’s body surface area (BSA), age, renal and hepatic function, prior treatments, and overall health status. Cytarabine has one of the widest dose ranges of any chemotherapy agent, from low-dose subcutaneous regimens to high-dose intravenous protocols. All dosing decisions must be made by an oncologist or hematologist experienced in cancer chemotherapy.

Adults

Children

Cytarabine is widely used in pediatric oncology, particularly for childhood ALL and AML. Dosing in children is generally based on body surface area (BSA), similar to adults, although specific pediatric protocols may differ in dose, schedule, and combination partners. For intrathecal administration in children, doses are typically adjusted based on age rather than BSA:

• Age 1–2 years: 30 mg intrathecally
• Age 2–3 years: 50 mg intrathecally
• Age ≥3 years: 70 mg intrathecally

Pediatric dosing for intravenous cytarabine follows age-specific protocols developed by collaborative clinical trial groups. Children generally tolerate cytarabine better than adults, with lower rates of cerebellar toxicity at equivalent doses. However, careful monitoring remains essential.

Elderly Patients

Older patients (generally defined as over 60–65 years in leukemia trials) may be at increased risk for cytarabine-related toxicity, particularly cerebellar neurotoxicity with high-dose regimens. The European LeukemiaNet (ELN) 2022 guidelines recommend that high-dose cytarabine (3 g/m²) should generally be avoided in patients over 60 years of age, with intermediate doses (1–1.5 g/m²) considered as an alternative. Renal function should be assessed before each cycle, as age-related decline in kidney function increases the risk of toxicity. For elderly patients who are unfit for intensive chemotherapy, lower-intensity approaches or non-cytarabine-based regimens may be more appropriate.

Missed Dose

Because cytarabine is administered in a hospital or clinic setting under the supervision of healthcare professionals, missed doses are managed by the treating medical team. If a dose is delayed or missed due to toxicity, blood count recovery, or other clinical reasons, the oncologist will determine whether to reschedule the dose, adjust the treatment schedule, or modify the regimen. Patients should never attempt to self-administer cytarabine or adjust their treatment schedule independently.

Overdose

There is no specific antidote for cytarabine overdose. An overdose would be expected to produce severe and prolonged myelosuppression, along with amplified versions of the drug’s known toxicities, particularly neurotoxicity and gastrointestinal damage. Treatment of overdose is supportive and symptomatic, including blood product transfusions, growth factor support, broad-spectrum antimicrobials for infection, and intensive monitoring. In the event of intrathecal overdose, immediate drainage of cerebrospinal fluid and replacement with isotonic saline is recommended, along with systemic dexamethasone to reduce inflammation. Intrathecal overdose can cause severe and potentially fatal ascending myelopathy. All suspected overdose cases require emergency management in an intensive care setting.

What Are the Side Effects of Cytarabin Hikma?

Like all chemotherapy medications, cytarabine can cause side effects. The type, severity, and frequency of side effects depend heavily on the dose, schedule, and route of administration. Standard-dose regimens have a different side effect profile compared to high-dose regimens. Not everyone will experience all of these side effects, and your medical team will implement measures to prevent or manage them. It is important to report any new or worsening symptoms to your healthcare team promptly.

The following frequency categories are used: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people).

Your medical team will closely monitor you for side effects throughout treatment and implement preventive and supportive measures as appropriate. These may include antiemetics for nausea and vomiting, antimicrobial prophylaxis, blood product transfusions, growth factor support (G-CSF), and corticosteroids for cytarabine syndrome or ocular prophylaxis. If you experience any new or troubling symptoms during or after treatment, report them to your healthcare team immediately.

How Should You Store Cytarabin Hikma?

Proper storage of Cytarabin Hikma is essential to maintain the stability and safety of the medication. As a hospital-administered medication, storage is primarily the responsibility of the pharmacy and nursing staff, but it is important for patients and caregivers to understand the basic storage requirements.

Cytarabin Hikma solution for injection should be stored at a temperature below 25°C (77°F). The vials should not be frozen, as freezing can alter the physical properties and stability of the solution. The medication should be protected from light and kept in its original carton until the time of use. Visual inspection should be performed before each use: the solution should be clear and free from visible particles; any discolored or cloudy solution should not be used.

Once the vial has been opened or the solution has been drawn into a syringe, it should be used promptly. The chemical and physical in-use stability may vary depending on the specific concentration and diluent used. Consult hospital pharmacy guidelines for the specific stability data applicable to the preparation method being used. From a microbiological point of view, the product should be used immediately after opening. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Unused portions of cytarabine solution and all materials that have come into contact with cytarabine (syringes, needles, infusion sets, protective equipment) must be disposed of as cytotoxic waste in accordance with local regulations for the handling and disposal of hazardous pharmaceutical waste. Cytarabine, like all cytotoxic agents, should be handled using appropriate protective measures including gloves, gowns, and safety goggles to minimize the risk of occupational exposure.

Do not use Cytarabin Hikma after the expiry date printed on the vial label and carton. The expiry date refers to the last day of the indicated month. Keep all medicines out of the reach and sight of children. Do not dispose of any medicines via wastewater or household waste – return unused or expired medicines to the hospital pharmacy for proper disposal.

What Does Cytarabin Hikma Contain?

Understanding the full composition of Cytarabin Hikma is important for identifying potential allergies to any of the components and for ensuring pharmaceutical compatibility when the drug is prepared for administration.

Active ingredient: Each milliliter of solution contains 100 mg of cytarabine. The drug is available in various vial sizes, with the total amount of cytarabine per vial depending on the vial volume (e.g., a 1 ml vial contains 100 mg, a 5 ml vial contains 500 mg, a 10 ml vial contains 1,000 mg, and a 20 ml vial contains 2,000 mg of cytarabine).

Excipients (inactive ingredients):

• Sodium chloride: Added to adjust the tonicity (osmotic balance) of the solution, making it closer to the body’s natural fluid concentration. This is particularly important for intrathecal administration.
• Hydrochloric acid and/or sodium hydroxide: Used to adjust the pH of the solution to an appropriate range (approximately pH 7.0–9.0) to ensure stability and reduce irritation at the injection site.
• Water for injections: The sterile solvent that forms the base of the solution.

Cytarabin Hikma solution is preservative-free, which is essential for intrathecal use, as preservatives such as benzyl alcohol can cause severe neurotoxicity when injected into the cerebrospinal fluid. If the formulation were to contain preservatives, it would be contraindicated for intrathecal administration. Always verify that the cytarabine product being used for intrathecal injection is explicitly labeled as preservative-free.

The solution appears as a clear, colorless to slightly yellowish liquid. Each vial is for single use only. Any remaining solution after the required dose has been withdrawn should be discarded as cytotoxic waste. Cytarabine is chemically stable at room temperature in its supplied form but should be protected from light to prevent photodegradation over extended periods.